53 related articles for article (PubMed ID: 19005267)
1. The effect of antiretroviral treatment of different durations in primary HIV infection.
Pantazis N; Touloumi G; Vanhems P; Gill J; Bucher HC; Porter K;
AIDS; 2008 Nov; 22(18):2441-50. PubMed ID: 19005267
[TBL] [Abstract][Full Text] [Related]
2. Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion.
Stirrup OT; Copas AJ; Phillips AN; Gill MJ; Geskus RB; Touloumi G; Young J; Bucher HC; Babiker AG;
HIV Med; 2018 Mar; 19(3):184-194. PubMed ID: 29230953
[TBL] [Abstract][Full Text] [Related]
3. Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts.
Touloumi G; Pantazis N; Pillay D; Paraskevis D; Chaix ML; Bucher HC; Kücherer C; Zangerle R; Kran AM; Porter K;
Clin Infect Dis; 2013 Mar; 56(6):888-97. PubMed ID: 23223594
[TBL] [Abstract][Full Text] [Related]
4. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.
Zolopa A; Andersen J; Powderly W; Sanchez A; Sanne I; Suckow C; Hogg E; Komarow L
PLoS One; 2009; 4(5):e5575. PubMed ID: 19440326
[TBL] [Abstract][Full Text] [Related]
5. Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure.
Lodi S; Phillips A; Fidler S; Hawkins D; Gilson R; McLean K; Fisher M; Post F; Johnson AM; Walker-Nthenda L; Dunn D; Porter K;
PLoS One; 2013; 8(9):e75608. PubMed ID: 24086588
[TBL] [Abstract][Full Text] [Related]
6. Short-course antiretroviral therapy in primary HIV infection.
; Fidler S; Porter K; Ewings F; Frater J; Ramjee G; Cooper D; Rees H; Fisher M; Schechter M; Kaleebu P; Tambussi G; Kinloch S; Miro JM; Kelleher A; McClure M; Kaye S; Gabriel M; Phillips R; Weber J; Babiker A
N Engl J Med; 2013 Jan; 368(3):207-17. PubMed ID: 23323897
[TBL] [Abstract][Full Text] [Related]
7. Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration.
Touloumi G; Pantazis N; Chaix ML; Bucher HC; Zangerle R; Kran AM; Thiebaut R; Masquelier B; Kucherer C; Monforte Ad; Meyer L; Porter K;
PLoS One; 2013; 8(7):e71174. PubMed ID: 23936260
[TBL] [Abstract][Full Text] [Related]
8. No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts.
Wright EJ; Grund B; Robertson KR; Cysique L; Brew BJ; Collins GL; Poehlman-Roediger M; Vjecha MJ; Penalva de Oliveira AC; Standridge B; Carey C; Avihingsanon A; Florence E; Lundgren JD; Arenas-Pinto A; Mueller NJ; Winston A; Nsubuga MS; Lal L; Price RW;
AIDS; 2018 May; 32(8):985-997. PubMed ID: 29424786
[TBL] [Abstract][Full Text] [Related]
9. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.
Grijsen ML; Steingrover R; Wit FW; Jurriaans S; Verbon A; Brinkman K; van der Ende ME; Soetekouw R; de Wolf F; Lange JM; Schuitemaker H; Prins JM;
PLoS Med; 2012; 9(3):e1001196. PubMed ID: 22479156
[TBL] [Abstract][Full Text] [Related]
10. The per-protocol effect of immediate versus deferred antiretroviral therapy initiation.
Lodi S; Sharma S; Lundgren JD; Phillips AN; Cole SR; Logan R; Agan BK; Babiker A; Klinker H; Chu H; Law M; Neaton JD; Hernán MA;
AIDS; 2016 Nov; 30(17):2659-2663. PubMed ID: 27782964
[TBL] [Abstract][Full Text] [Related]
11. Multilevel ordinal model for CD4 count trends in seroconversion among South Africa women.
Dessie ZG; Zewotir T; Mwambi H; North D
BMC Infect Dis; 2020 Jun; 20(1):447. PubMed ID: 32576220
[TBL] [Abstract][Full Text] [Related]
12. If we can't get what we want, can we get what we need? optimizing use of antiretroviral therapy in the current era.
Baker JV; Henry K
Ann Intern Med; 2011 Apr; 154(8):563-5. PubMed ID: 21502654
[No Abstract] [Full Text] [Related]
13. Individualized treatment rules: generating candidate clinical trials.
Petersen ML; Deeks SG; van der Laan MJ
Stat Med; 2007 Nov; 26(25):4578-601. PubMed ID: 17450501
[TBL] [Abstract][Full Text] [Related]
14. A study on the dynamics of temporary HIV treatment to assess the controversial outcomes of clinical trials: An in-silico approach.
Mancini E; Quax R; De Luca A; Fidler S; Stohr W; Sloot PMA
PLoS One; 2018; 13(7):e0200892. PubMed ID: 30021018
[TBL] [Abstract][Full Text] [Related]
15. More data, less information? Potential for nonmonotonic information growth using GEE.
Shoben AB; Rudser KD; Emerson SS
J Biopharm Stat; 2017; 27(1):135-147. PubMed ID: 27049897
[TBL] [Abstract][Full Text] [Related]
16. The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment.
Pantazis N; Touloumi G; Meyer L; Olson A; Costagliola D; Kelleher AD; Lutsar I; Chaix ML; Fisher M; Moreno S; Porter K;
AIDS; 2016 Mar; 30(6):879-88. PubMed ID: 26636925
[TBL] [Abstract][Full Text] [Related]
17. Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysis.
Chen J; Han X; An M; Liu J; Xu J; Geng W; Ji Y; Shang H
PLoS One; 2013; 8(12):e82461. PubMed ID: 24324793
[TBL] [Abstract][Full Text] [Related]
18. A cure for AIDS: a matter of timing?
Shytaj IL; Savarino A
Retrovirology; 2013 Nov; 10():145. PubMed ID: 24267982
[TBL] [Abstract][Full Text] [Related]
19. Socially-integrated transdisciplinary HIV prevention.
Friedman SR; Downing MJ; Smyrnov P; Nikolopoulos G; Schneider JA; Livak B; Magiorkinis G; Slobodianyk L; Vasylyeva TI; Paraskevis D; Psichogiou M; Sypsa V; Malliori MM; Hatzakis A
AIDS Behav; 2014 Oct; 18(10):1821-34. PubMed ID: 24165983
[TBL] [Abstract][Full Text] [Related]
20. The detection and management of early HIV infection: a clinical and public health emergency.
Smith MK; Rutstein SE; Powers KA; Fidler S; Miller WC; Eron JJ; Cohen MS
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S187-99. PubMed ID: 23764635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
